# Safety and Immunogenicity Study of COVID-19 Protein Subunit Recombinant Vaccine

> **NCT05313035** · PHASE2,PHASE3 · COMPLETED · sponsor: **PT Bio Farma** · enrollment: 360 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** SARS-CoV-2 protein subunit recombinant vaccine
- **BIOLOGICAL:** placebo

## Key facts

- **NCT ID:** NCT05313035
- **Lead sponsor:** PT Bio Farma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-13
- **Primary completion:** 2022-07-22
- **Final completion:** 2023-02-28
- **Target enrollment:** 360 (ACTUAL)
- **Last updated:** 2023-04-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05313035

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05313035, "Safety and Immunogenicity Study of COVID-19 Protein Subunit Recombinant Vaccine". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05313035. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*